News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
385,103 Results
Type
Article (26563)
Company Profile (115)
Press Release (358425)
Section
Business (101645)
Career Advice (527)
Deals (17954)
Drug Delivery (68)
Drug Development (38526)
Employer Resources (77)
FDA (10617)
Job Trends (9959)
News (174463)
Policy (20557)
Tag
Academia (2102)
Africa (507)
Alliances (28213)
Alzheimer's disease (741)
Approvals (10587)
Arizona (79)
Artificial intelligence (50)
Asia (20820)
Australia (3723)
Bankruptcy (143)
Best Places to Work (8648)
Biosimilars (43)
Biotechnology (63)
C2C Services and Suppliers (41985)
California (898)
Canada (577)
Cancer (151)
Career advice (485)
Cell therapy (48)
China (70)
Clinical research (30276)
Collaboration (59)
Colorado (38)
Connecticut (47)
COVID-19 (2099)
Cystic fibrosis (43)
Data (104)
Diabetes (46)
Diagnostics (4561)
Drug pricing (62)
Earnings (32468)
Employer resources (66)
Europe (46239)
Events (69645)
Executive appointments (72)
FDA (10740)
Florida (142)
Funding (64)
Gene therapy (39)
Georgia (45)
GLP-1 (278)
Government (4033)
Healthcare (14768)
Hotbed/Location (260435)
Idaho (35)
Illinois (159)
Indiana (125)
Infectious disease (2117)
Inflammatory bowel disease (57)
Interviews (59)
IPO (7595)
Job creations (1399)
Job search strategy (448)
Kansas (71)
Layoffs (150)
Legal (3869)
Maine (54)
Manufacturing (44)
Maryland (245)
Massachusetts (785)
Medical device (9120)
Medtech (9121)
Mergers & acquisitions (10317)
Metabolic disorders (155)
Michigan (69)
Minnesota (109)
Neuroscience (813)
New Jersey (331)
New York (297)
NextGen Class of 2024 (4959)
Non-profit (3903)
North Carolina (391)
Northern California (443)
Obesity (105)
Ohio (62)
Opinion (100)
Pennsylvania (373)
People (31653)
Phase I (9627)
Phase II (11872)
Phase III (10799)
Pipeline (56)
Policy (36)
Postmarket research (1565)
Preclinical (3059)
Press Release (47)
Rare diseases (67)
Real estate (2822)
Regulatory (13276)
Research institute (1897)
Resumes & cover letters (41)
South America (663)
Southern California (358)
Startups (2071)
Texas (96)
United States (4758)
Utah (35)
Vaccines (360)
Washington State (172)
Weight loss (84)
Date
Today (2)
Last 7 days (338)
Last 30 days (1288)
Last 365 days (22742)
2024 (15375)
2023 (24260)
2022 (33690)
2021 (37129)
2020 (37573)
2019 (33254)
2018 (24881)
2017 (17710)
2016 (18859)
2015 (21430)
2014 (16060)
2013 (12721)
2012 (13464)
2011 (13905)
2010 (11929)
385,103 Results for "guardant health".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer
Guardant Health, Inc., a leading precision oncology company, announced the launch of a new version of its Guardant360 TissueNext test that expands the number of genes it identifies in a tumor tissue sample to 498.
June 4, 2024
·
4 min read
Biotech Bay
Guardant Health to Participate in Upcoming Investor Conferences - May 22, 2024
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences.
May 22, 2024
·
1 min read
Biotech Bay
Guardant Health to Participate in Upcoming May 2024 Investor Conferences
Guardant Health, Inc., a leading precision oncology company, announced the company will participate in the following investor conferences.
May 7, 2024
·
1 min read
Business
Guardant Health Named to TIME100 Most Influential Companies
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced its inclusion in the fourth-annual TIME100 Most Influential Companies list, highlighting companies making an extraordinary impact around the world.
May 31, 2024
·
2 min read
Biotech Bay
Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced certification for its Guardant360® CDx blood test under the European Union’s In Vitro Diagnostic Regulation (IVDR 2017/746).
May 21, 2024
·
8 min read
Deals
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 22, 2024, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 215,601 shares of its common stock to 94 new non-executive employees and non-qualified stock option awards to purchase an aggregate of 98,076 shares of its common stock to three new non-executive employees.
May 17, 2024
·
2 min read
Business
Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
Guardant Health, Inc., a leading precision oncology company, reported financial results for the quarter ended March 31, 2024.
May 9, 2024
·
16 min read
Biotech Bay
Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening
Guardant Health, Inc. today announced the company and its research collaborators will present data from 16 studies highlighting the role of Guardant blood tests and real-world data in advancing precision oncology and cancer screening at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting, May 31-June 4 in Chicago.
May 30, 2024
·
7 min read
Biotech Bay
FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23
Guardant Health, Inc. today announced the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration Medical Devices Advisory Committee is scheduled to review the premarket approval (PMA) application for the company’s Shield™ blood test for colorectal cancer (CRC) screening on Thursday, May 23, 2024.
April 22, 2024
·
3 min read
Biotech Bay
Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from two real-world studies at the 2024 Digestive Disease Week (DDW) meeting in Washington, DC, highlighting the value of the company’s Shield™ test in colorectal cancer (CRC) screening.
May 16, 2024
·
3 min read
1 of 38,511
Next